Cipher Pharmaceuticals Inc (CPH) Upgraded at Bloom Burton

Bloom Burton upgraded shares of Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) from a hold rating to a buy rating in a research note released on Friday morning.

A number of other equities research analysts have also recently weighed in on CPH. CIBC raised their price target on Cipher Pharmaceuticals from C$5.25 to C$6.90 in a report on Friday, January 13th. TD Securities reaffirmed a hold rating and set a C$4.75 price target on shares of Cipher Pharmaceuticals in a report on Friday, March 3rd.

Cipher Pharmaceuticals (TSE:CPH) opened at 5.55 on Friday. The company’s market cap is $146.07 million. Cipher Pharmaceuticals has a 1-year low of $3.50 and a 1-year high of $8.00. The stock has a 50 day moving average price of $4.60 and a 200 day moving average price of $4.47.

COPYRIGHT VIOLATION WARNING: “Cipher Pharmaceuticals Inc (CPH) Upgraded at Bloom Burton” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/05/18/cipher-pharmaceuticals-inc-cph-upgraded-at-bloom-burton.html.

In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin purchased 10,500 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The stock was purchased at an average cost of C$5.35 per share, with a total value of C$56,175.00.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

What are top analysts saying about Cipher Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cipher Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit